Advertisement

BW Businessworld

Liquid Biopsy Aided Genetic Analyses For Personalised Management Of Cancer

Genetic analyses are set to become important tests for therapies in many diseases, apart from cancer in the future. Liquid biopsy based DNA analyses, therefore, represent a huge leap forward in enabling delivery of healthcare

Strand has recently launched a portfolio of liquid biopsy tests for management of cancer. The Liquid Biopsy Test developed in India is at par with the best ones available worldwide and reflects Strand's ideology of bringing affordable excellence to the Indian healthcare community.

Cancer treatment, for the longest time, has been based on a 'One Therapy Fits All' approach. However, it is obvious that this kind of an approach often entails that the patients and the disease develop a resistance to a kind of treatment. Since all changes in cancers are genetic, gene expression profiling is done to enquire the expression of genes. Gene expression profiling is used to precisely classify tumors to determine the cancer care treatment. The ability to obtain a 'genetic signature' of cancers on a per patient basis has the potential for delivery of personalized treatment to every cancer patient. Liquid Biopsy is a game-changer that can be used to identify genetic signatures through a simple blood draw.

The powerful tool enables early and precise detection of tumor presence, cancer recurrence, and response to therapy compared to any other method used in the medical industry. In this particular test, scientists harvest DNA that the cancerous cells shed in the bloodstream and create a list of mutations which then serve as a genetic identifier for the patient's cancer.

Cancer is an epidemic that has massive emotional and financial burden on the patient as well as their family and friends. Cases of lung cancer remain critical where the recurrence or detection is difficult due to the absence of a substantial amount of solid tissue for biopsy. Post the expensive chemo- and radiotherapy, the patient often has to wait for their yearly PET-CT scan to know if the cancer will relapse. In such medical conditions, Liquid Biopsy has proven to be a boon as it reduces the number of biopsies drastically and provides confirmed results through blood samples.

By providing a glimpse of tumor DNA, throughout the course of the disease, Liquid Biopsy Tests enable oncologists to understand the way a patient's cancer responds to chemotherapy, reasons for non-responsiveness to chemotherapy and resistance towards specific drugs. The ability to track changes in a patient's cancer cells allows doctors and scientists to literally 'walk in-step with a patient's cancer' and decide how and when to change chemotherapy drugs for that patient.

Genetic analyses are set to become important tests for therapies in many diseases, apart from cancer in the future. Liquid biopsy based DNA analyses, therefore, represent a huge leap forward in enabling delivery of healthcare.

Disclaimer: The views expressed in the article above are those of the authors' and do not necessarily represent or reflect the views of this publishing house. Unless otherwise noted, the author is writing in his/her personal capacity. They are not intended and should not be thought to represent official ideas, attitudes, or policies of any agency or institution.


Tags assigned to this article:
opinion Liquid Biopsy cancer CT scan


Dr Vijay Chandru

Dr. Chandru has three decades of experience straddling various geographies, academic environments and industries. He was elected a Fellow of the Indian Academies of Sciences and Engineering. Dr. Chandru is an Adjunct Faculty at the Centre for Biosystems Science and Engineering (BSSE) at IISc in Bangalore.

More From The Author >>
sentifi.com

Top themes and market attention on:


Advertisement